COMP <GO>
ABUS vs DSGN // RSI-14 & 200D SMA MOMENTUM
Arbutus Biopharma Corporation (NASDAQ) VS. Design Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ABUS 2
— DSGN 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: DSGN
LAST: $4.00 (-4.99%) • MKT CAP: $645.3M
rsi-technicals
41.0
LAST: $10.15 (-4.96%) • MKT CAP: $668.4M
rsi-technicals
43.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABUS VS. DSGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABUS | DSGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -32.10% | -2.90 | DSGN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.04% | -7.88% | +1.84 | ABUS | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 128.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.34 | 26.00 | -24.66 | DSGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | ABUS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 41.0 | 43.3 | -2.30 | DSGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $645.3M | $668.4M | -$23.1M | DSGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABUS REV | DSGN REV | ABUS GROSS % | DSGN GROSS % | ABUS FCF | DSGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.1M | $222.5M | — | — | -$39.6M | -$54.6M |
| FY 2024 | $6.2M | $174.7M | — | — | -$65.0M | -$43.4M |
| FY 2023 | $18.1M | $218.9M | — | — | -$85.9M | -$58.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABUS // BETA —
DSGN // BETA —